|
|
 |
|
Viewing report
|
|
|
|
Molybdenum-99: Privatising Nuclear Medicine
Business Monitor International, June 2011, Pages: 18
This Special Report from Business Monitor International examines the global supply of Molybdenum- 99, looking at the likelihood of price rises and the implications of investment.
The report is split into the following topics:
- Molybdenum-99, the Birth of a New Commodity
- The Demand for 99mTc
- Why is the Price of 99Mo Artificially Low?
- How Much Will the Price Rise and When?
- Could the Market Experience an Overcapacity?
- The Processing Bottleneck
- The Importance of Non-Proliferation and the Switch to LEU
- Where to Invest–Reactors vs Cyclotrons
- Potential Investors and Current Market Leaders Client Benefits
This Special Report draws upon the expertise of BMI’s Pharmaceutical and Healthcare analysts to provide an insight into the current market, the need for price changes and the future demand for Molybdenum-99 (99Mo). The need to have a continuous supply of medical isotopes has the potential to transform this product from a publicly-subsidised by-product to a lucrative commodity.
This report believes the rewards for investing while risks surrounding price increases remains, will secure a better return on investment in the long term. The report is based on existing studies combined with BMI’s proprietary growth forecasts to quantify the investment rewards, risks and opportunities. In addition, it projects the best investment strategies, looking at the current market players and the available isotope production technologies.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
